Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
Status:
Recruiting
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
Brain tumor treatment is hampered by the blood-brain barrier (BBB). This barrier prevents
drugs carried in the bloodstream from getting into the brain. If the BBB can be opened,
making it temporarily more permeable, drugs may able to better reach the brain tumor. In this
trial we will implant a novel device with 9 ultrasound emitters, allowing temporary and
reversible opening of the BBB to maximize brain penetration of drugs that modulate the immune
system. The device will be implanted after radiation is completed. Immune modulating drugs
will be given every 3 weeks in conjunction with activation of the device to open the BBB.
The objectives of this trial are to establish whether it is safe and feasible to administer
immune modulating drugs in this manner, and identify whether the treatment is effective in
treating glioblastoma.